Business Context and Reporting Period
This Form 8-K filing by Molina Healthcare, Inc. reports corporate governance changes effective March 11, 2013. The company expanded its Board of Directors from nine to eleven members.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of new directors and does not contain financial performance data.
Material Changes
The primary material change is the expansion of the Board of Directors and the election of three new directors:
- Steven James: Elected as a Class II director to fill an existing vacancy. His term expires at the 2013 annual meeting.
- Dale Wolf: Elected as a new Class III director. His election requires shareholder ratification at the 2013 annual meeting.
- Daniel Cooperman: Elected as a new Class I director. His election requires shareholder ratification at the 2013 annual meeting.
Guidance, Outlook, and Management Commentary
There is no financial guidance or outlook provided in this filing. Management commentary is limited to the background of the new directors and the compensation structure:
- Compensation: The new directors will receive standard compensation amounts payable to non-employee directors as described in the definitive proxy statement filed on March 26, 2012.
- Committee Assignments: Assignments for the new directors will be determined at a later date.
- Director Backgrounds:
- Mr. James is a retired audit partner from Ernst & Young with 30 years of experience in health and managed care.
- Mr. Wolf is the Executive Chairman of Correctional Healthcare Companies, Inc. and formerly served as CEO of Coventry Health Care, Inc.
- Mr. Cooperman is Of Counsel with Bingham McCutchen LLP and formerly served as General Counsel for Apple Inc. and Oracle Corporation.
Investor Verification Checklist
- Verify the ratification of Dale Wolf and Daniel Cooperman at the 2013 annual meeting of stockholders.
- Review the definitive proxy statement filed on March 26, 2012, for details on non-employee director compensation.
- Monitor future announcements regarding the specific committee assignments for the three new directors.
- Confirm that no undisclosed arrangements or transactions exist between the new directors and the company, as stated in the filing.